Trade Sage Therapeutics, Inc. - SAGE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023318% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001096% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.59 |
| Open | 7.57 |
| 1-Year Change | -41.41% |
| Day's Range | 7.54 - 7.76 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2025 | 7.59 | -0.12 | -1.56% | 7.71 | 7.86 | 7.58 |
| Apr 22, 2025 | 7.63 | 0.13 | 1.73% | 7.50 | 7.69 | 7.40 |
| Apr 21, 2025 | 7.42 | 0.12 | 1.64% | 7.30 | 7.61 | 7.22 |
| Apr 17, 2025 | 7.40 | 0.14 | 1.93% | 7.26 | 7.51 | 7.26 |
| Apr 16, 2025 | 7.35 | 0.00 | 0.00% | 7.35 | 7.44 | 7.25 |
| Apr 15, 2025 | 7.52 | 0.19 | 2.59% | 7.33 | 7.61 | 7.33 |
| Apr 14, 2025 | 7.37 | 0.13 | 1.80% | 7.24 | 7.44 | 7.20 |
| Apr 11, 2025 | 7.13 | 0.36 | 5.32% | 6.77 | 7.17 | 6.74 |
| Apr 10, 2025 | 6.90 | 0.16 | 2.37% | 6.74 | 6.99 | 6.66 |
| Apr 9, 2025 | 6.87 | 0.62 | 9.92% | 6.25 | 7.05 | 6.08 |
| Apr 8, 2025 | 6.37 | -0.38 | -5.63% | 6.75 | 6.86 | 6.31 |
| Apr 7, 2025 | 6.62 | 0.03 | 0.46% | 6.59 | 6.88 | 6.37 |
| Apr 4, 2025 | 6.83 | -0.36 | -5.01% | 7.19 | 7.24 | 6.74 |
| Apr 3, 2025 | 7.35 | -0.23 | -3.03% | 7.58 | 7.61 | 7.32 |
| Apr 2, 2025 | 7.75 | 0.05 | 0.65% | 7.70 | 7.94 | 7.66 |
| Apr 1, 2025 | 7.84 | -0.01 | -0.13% | 7.85 | 7.90 | 7.69 |
| Mar 31, 2025 | 7.92 | -0.12 | -1.49% | 8.04 | 8.05 | 7.86 |
| Mar 28, 2025 | 8.26 | -0.37 | -4.29% | 8.63 | 8.77 | 8.21 |
| Mar 27, 2025 | 8.64 | 0.13 | 1.53% | 8.51 | 8.68 | 8.46 |
| Mar 26, 2025 | 8.56 | 0.11 | 1.30% | 8.45 | 8.65 | 8.40 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Sage Therapeutic Company profile
About SAGE Therapeutics Inc
SAGE Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD), in adults. The Company's products also include ZULRESSO (Brexanolone) CIV Injection, Zuranolone (SAGE-217), SAGE-324 and SAGE-718. Its next advanced product candidate is SAGE-217, is an oral compound that is in Phase III clinical development in PPD and depressive disorder (MDD). Zuranolone is a neuroactive steroid that, like brexanolone, is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing and conducting a placebo-controlled Phase II clinical trial evaluating the safety and efficacy of SAGE-324 in the treatment of essential tremor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, SAGE Therapeutics Inc revenues decreased 99% to $6.3M. Net loss totaled $457.9M vs. income of $606.1M. Revenues reflect Collaboration revenue decrease from $1.11B to $0K, Product decrease of 6% to $6.3M. Net loss reflects Stock-based Compensation in R&D increase of 17% to $49.7M (expense), Stock-based Compensation in SGA increase of 6% to $54.9M (expense), Other income (expense).
Equity composition
Common Stock, $0.0001 Par, 07/14, auth. 120M shares,. 24,961,926 issd,. Insiders owns approx. 20.03%.
| Industry: | Bio Therapeutic Drugs |
215 1st St
CAMBRIDGE
MASSACHUSETTS 02142
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com